Growth hormone peptides compared

Ipamorelin vs sermorelin

A growth hormone secretagogue and a growth hormone-releasing hormone analog, with each figure tied to its own label or study.

A 1998 study describes ipamorelin as a pentapeptide and the first GHRP-receptor agonist with a selectivity for GH release similar to that of GHRH, and a review describes sermorelin as a 29 amino acid analogue of human GHRH.1,2 In healthy men given 15-minute infusions, ipamorelin had a terminal half-life of 2 hours, and a sermorelin prescribing text on RxList gives 11 to 12 minutes after intravenous or subcutaneous dosing.3,4

FDA states that the US Geref products, 0.5 mg and 1.0 mg base per vial, were discontinued and not withdrawn for reasons of safety or effectiveness, and FDA placed ipamorelin acetate in 503B category 2, its list of compounding substances that may present significant safety risks, on September 29, 2023.5,6 No label for ipamorelin was found.

FactIpamorelinSermorelin
What it isA pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, with a selectivity for GH release similar to that of GHRH1The shortest synthetic peptide with the full biological activity of GHRH2
How it comesNo label was found; given as 15-minute infusions in a pharmacokinetic study and as twice-daily intravenous infusions in a surgery trial3,9Geref, by subcutaneous injection; discontinued in the US, not for reasons of safety or effectiveness4,5
Half-lifeA terminal half-life of 2 hours after 15-minute infusions in healthy men3
  • 11 to 12 minutes after intravenous or subcutaneous dosing, in a prescribing text on RxList4
  • 6 to 7 minutes after intravenous dosing, on the Irish label10
Studied doses
  • Healthy men: 4.21 to 140.45 nmol/kg infused over 15 minutes, eight men at each of 5 dose levels3
  • Surgery trial: 0.03 mg/kg or placebo by intravenous infusion twice daily, from postoperative day 1 to 7 or discharge9
  • RxList prescribing text: 0.2 to 0.3 mg once daily at bedtime, subcutaneous4
  • Trial in old men: GHRH 1-29 at 0.5 mg and 1 mg, subcutaneous, twice daily for 14 days each11
StatusFDA placed ipamorelin acetate on its 503B list of substances that may present significant safety risks on September 29, 2023, naming a risk of immunogenicity for certain routes6. WADA names ipamorelin among growth hormone secretagogues, prohibited at all times12FDA: the US Geref products were discontinued, not withdrawn for reasons of safety or effectiveness5. WADA names sermorelin among GHRH analogues in S2, prohibited at all times12

Get the app

Contents6
  1. 1How they differ
  2. 2Levels after one dose
  3. 3Logged in Milligram
  4. 4What is not known
  5. 5References
  6. 6Related pages

Last reviewed . Sources are listed below.

How they differ

A review states that sermorelin stimulates growth hormone secretion from the anterior pituitary, and a 1998 study states that ipamorelin stimulates GH release via a GHRP-like receptor.2,1 In swine in that study, ipamorelin did not release ACTH or cortisol at levels significantly different from GHRH stimulation, even at doses more than 200-fold higher than the ED50 for GH release.1

Levels after one dose

Ipamorelin and sermorelin after one dose, each as a share of that dose. Each curve follows the half-life its compound page draws, from the Milligram app's model; the sourced half-lives are in the facts table.

Logged in Milligram

  • Ipamorelin: 4% of people who logged a dose in Milligram logged it in the 90 days to 15 November 2026.
  • Sermorelin: Too few people logged it to show a share.

Shares of people who logged a dose in Milligram in the 90 days to 15 November 2026, shown only where at least 50 people logged three or more doses of the compound.

What is not known

A sermorelin prescribing text on RxList states that no metabolism studies have been performed in humans, and a review states that sermorelin has not been directly compared with somatropin.4,2 A 2026 review notes no long term safety data for ipamorelin, and FDA states that a published study identified serious adverse events, including death, when ipamorelin was given intravenously, and that it lacks sufficient information on certain other injectable routes.7,6 A sermorelin prescribing text on RxList gives a mean absolute bioavailability of about 6% after subcutaneous dosing; for ipamorelin, no figure measured in people after injection was found, and a study in rats estimated its bioavailability after intranasal application at about 20%.4,8 No human trial was found that gave both peptides; a 1998 study compared ipamorelin with GHRH stimulation in swine, and its abstract does not say which form of GHRH was used.1

References

  1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Journal article (rat and swine study), 1998. PMID 9849822
  2. Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. Journal article (review), 1999. PMID 18031173
  3. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Journal article (clinical trial), 1999. PMID 10496658
  4. RxList. Sermorelin Acetate (Sermorelin): Side Effects, Uses, Dosage, Interactions, Warnings. Drug label text, 2001. rxlist.com
  5. Food and Drug Administration. Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Regulator notice, 2013. govinfo.gov
  6. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Regulator web page, 2026. fda.gov
  7. Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Review article, 2026. PMC13322892
  8. Johansen PB, Hansen KT, Andersen JV, Johansen NL. Pharmacokinetic evaluation of ipamorelin and other peptidyl growth hormone secretagogues with emphasis on nasal absorption. Journal article (rat study), 1998. PMID 9879640
  9. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Journal article (phase 2 trial), 2014. PMID 25331030
  10. Irish Medicines Board. Summary of Product Characteristics: Geref 50 (sermorelin acetate). Regulator document, 2006. assets.hpra.ie
  11. Corpas E, Harman SM, Pineyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal article (clinical trial), 1992. PMID 1379256
  12. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. Regulator document, 2026. wada-ama.org